Profile: PharmAthene Inc (PIP.A)
2 Jul 2015
Pharmathene, Inc. (Pharmathene), incorporated on April 25, 2005, is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines, including SparVax, which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine, and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger, which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds, including nerve gases and pesticides, and Valortim, which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection.
SparVax: Recombinant Protective Antigen (rPA)-based Anthrax Vaccine (Liquid
SparVax is a liquid rPA anthrax vaccine designed to protect against inhalational anthrax, which is a lethal form of B. anthracis infection in humans. The vaccine induces anti-Protective Antigen (PA), antibodies in clinical trials in healthy human volunteers and in animal models of inhalational anthrax. Vaccination with SparVax can generates titers of antibodies and protection in rabbits and non-human primates that are subsequently exposed to inhalation doses of anthrax spores. One Phase I and two Phase II clinical trials have been completed involving approximately 770 individuals. Data from these trials demonstrated that SparVax is generally well tolerated and immunogenic.
Valortim: Anthrax Monoclonal Antibody
Valortim is a fully human monoclonal antibody designed to protect against and treat human inhalational anthrax, as both post-exposure prophylaxis (before symptoms manifest) and post-exposure therapy (once symptoms are evident). Valortim utilizes a mechanism of action similar to the natural immune response. Valortim is designed to bind to PA and protect the cells from damage by the anthrax toxins. In non-clinical studies, animals were protected against this disease when Valortim was administered following an aerosol challenge of anthrax spores, demonstrating that Valortim induces recovery and survival in animals exposed to inhalational anthrax. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS). Valortim has received Fast Track designation from the FDA as well as orphan drug status.
The Company competes with Emergent Biosolutions, Inc., Emergent BioSolutions, Inc., Green Cross, Panacea Biotec Ltd., PaxVax, Bavarian Nordic, IBio, Pfenex, Soligenix, Vaxin, GlaxoSmithKline plc., Elusys Therapeutics, Inc., Emergent BioSolutions, Inc., IQ Corporation BV, Bayer AG, Ortho-McNeil Pharmaceuticals, Countervail Corporation, Pfizer, Inc., Protalix BioTherapeutics, Inc. Dynport Vaccine Company, LLC. and Baxter Healthcare Corporation.
1 Park Pl Ste 450
ANNAPOLIS MD 21401-3481